Rotigotine provides clinically apposite improvements in RLS symptoms: Look
UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical look, published in the quarterly Change Disorders, showing that Neupro® (rotigotine transdermal method, 2 and 3 mg/24 hours) provided even, clinically related improvements in symptoms of Repair Legs Syndrome (RLS). The bookwork also showed euphoric rates of accomplished excuse incomparable with rotigotine 2 mg or 3 mg/24 hours.
“In this analyse rotigotine alleviated RLS symptoms in patients with steady to inclement RLS in excess of a treatment aeon of six months, which is the longest reported double-blind treatment duration maintained in the U.S. to the assessment of RLS treatments,” said Dr. Richard Allen, from Activity be contingent of Neurology, John Hopkins University, Baltimore, Md., U.S. “One consequence from this contemplation was a enormous fee of intact deliverance from all RLS symptoms. About song of three in days gone by to some degree to dangerously sinister patients was without any RLS symptoms after 6 months of treatment with either 2 or 3 mg of rotigotine.”
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
